Navigation Links
StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
Date:2/28/2013

LONDON, February 28, 2013 /PRNewswire/ --

Markets responded well to Fed chief Ben Bernanke's remarks about the stimulus policy. On the other hand, there are some worries about the ongoing Sequestration debate as well. However, broader indices remained in the green and The Dow Jones closed 1.26% higher at 14,075.37, the S&P 500 closed 1.27% higher at 1,515.99, and the NASDAQ closed 1.04% higher at 3,162.26. Our research team took a look at major drug makers stocks including companies like Eli Lilly & Co. (NYSE: LLY), Bristol Myers Squibb Co. (NYSE: BMY), Astex Pharmaceuticals Inc. (NASDAQ: ASTX) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has issued technical analysis and charting reports on LLY, BMY, ASTX and RPTP. Download these free reports now at http://www.stockcall.com/todaysopinions

Eli Lilly & Co. is currently in a bullish mode as the stock created a new 52-week high price in its latest trading session. The stock closed the session at $54.80, up 0.68 percent. Eli Lilly traded in the range of $54.26 and $54.99 during the session. Its first support level is at $53.83 and upon breaching this level, the stock may go down to $52.46 level. On the upside, Eli Lilly & Co.'s stock may touch $57.44 level. The stock has traded in the range of $38.56 and $54.99 in the past 52 weeks and it grew by 40 percent during the same time period. On a Year-to-Date basis, the stock is up 11.11 percent. Download the free research on LLY today by registering at http://www.StockCall.com/LLY022813.pdf

Bristol Myers Squibb Co.'s shares also touched a new 52-week high in its latest trading session, ending the day 1.95 percent higher at $37.10. The stock fell to an intra-day low of $36.31, while its intra-day high stood at $37.22. With the upward movement, the stock grew more than 13 percent this year, compared to a gain of 6.3 percent for the S&P 500. The stock has strong support at around $37.03, as it shows a bullish trend. The stock is trading below than its 20-day and 50-day moving averages. Sign up and have access to our free report on BMY at http://www.StockCall.com/BMY022813.pdf

Astex Pharmaceuticals traded in the range of $3.08 and $3.24 in its latest trading session and ended it at $3.19, up 1.92 percent. The stock's 52 weeks range stands at $1.57 and $3.55. Astex Pharma. is up 62.76 percent in the past 12 months, while it gained 9 percent so far this year. The stock is in a bullish mode and may find its first support level at $3.17. It is trading below its 20-day moving average of $3.29 but above its 50-day average price of $3.14. Sign up and read the complimentary report on ASTX at http://www.StockCall.com/ASTX022813.pdf

Shares of Raptor Pharma ended their previous trading session marginally lower at $4.98, down 0.40 percent. The stock lost more than 14 percent this year, in contrast to the broad market. The stock has slipped from $5.03 resistance level. It has support at around $4.87 at the moment. With its downward movement, Raptor is trading below its 20-day moving average price. The stock may touch $5.08 level in the coming trading sessions. The free report on RPTP can be downloaded by signing up now at http://www.StockCall.com/RPTP022813.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
2. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
3. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
4. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
5. Omnyx Share Their Insight on Agile Software Development for Medical Devices
6. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
7. GlaxoSmithKline Share Their Insight on Understanding DDI With a View to Better Prediction and Control
8. Pro-Dex Provides Insight Into Fiscal 2013 Operating Plan And Preliminary Results For Fiscal 2012
9. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
10. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
11. New Survey Reveals How Patients Choose Their Pharmacy; AccentHealth Garners Consumer Insights from the Waiting Room
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):